Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 16 GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway Authors Xiang J , Qin L , Zhong J, Xia N , Liang Y Received 12 June 2023 Accepted for publication 5 August 2023 Published 15 August 2023 Volume 2023:16 Pages 24332446 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Konstantinos Tziomalos Jie Xiang, 1 Liyan Qin, 2 Jinling Zhong, 3 Ning Xia, 2 Yuzhen Liang 3 1 Department of Clinical Nutrition, The First Affiliated Hospital of Guangxi Medical University, Nanning, Peoples Republic of China
If you are of childbearing potential, use effective contraception and discontinue Wegovy at least 2 months before a planned pregnancy
Further reading and references Wilding et al: Once-Weekly Semaglutide in Adults with Overweight or Obesity Moiz et al: Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes Rubino et al: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Bolek et al: Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity About the authorView full bio Dr Nienke Lees Women's Health Service Lead MB BChir, MA, MRCS(ENT), DOHNS, MRCGP, LMCA Dr Nienke Lees is the Women's Health Service Lead at Genwell
Large observational studies have reported that GLP-1 RA use is associated with a 2330% reduction in CRC risk [18, 19]
Those with Gastrointestinal, Cardiovascular, or Neurological Conditions To support organ health and manage related symptoms
